ArticleOpen respiratory archives
GEMA 5.3. Spanish Guideline on the Management of Asthma.
Article in Open respiratory archives. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.Advances in therapy · 2026Trial
- Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.The European respiratory journal · 2024Trial
- [Sleep disorders associated with montelukast in children with respiratory allergy].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Real-world impact of mepolizumab on symptom control and health utility in severe chronic rhinosinusitis with nasal polyps: the RINOSUR 2.0 multicenter cohort study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Effect of Delayed Initiation of Mepolizumab on EXACTO Scale Scores, Clinical Remission SEPAR-REMAS Criteria, and Functional Outcomes in Uncontrolled Severe Asthma: A Real-World Study.Medical sciences (Basel, Switzerland) · 2026Observational
- Asthma remission with benralizumab therapy in severe eosinophilic Indian asthmatics.Lung India : official organ of Indian Chest Society · 2026Article
- Should household air quality monitoring be considered in selected patients with asthma and COPD?BMJ open respiratory research · 2026Observational
- Long-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain.Journal of clinical medicine · 2026Article
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- A Pragmatic RCT of FF/UMEC/VI in Patients with Uncontrolled Asthma: PERFORM Protocol.Pulmonary therapy · 2026Article
- Optimizing the Use of Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- Effectiveness of Mepolizumab in Severe Uncontrolled Asthma Associated or Not with EGPA Based on the Exacto Scale and Separ-Remas Criteria.Journal of asthma and allergy · 2026Article
- Opinion and Knowledge of Pulmonologists, Primary Care Physicians, and Nurses About Inhaled Therapy in COPD. Inhal-Epoc Survey.International journal of chronic obstructive pulmonary disease · 2026Article
- Evaluation of the concordance of asthma remission definitions according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma.Frontiers in pharmacology · 2026Article
- Vietnamese Consensus on the Structure and Content of Asthma Action Plan.Journal of clinical medicine · 2025Article
- Impact of Physical Exercise on Adult Asthma Control: A Randomized Clinical Trial.Healthcare (Basel, Switzerland) · 2025Article
- Discontinuation of biologic therapy in severe asthma: Evidence and strategies for safe withdrawal: A scoping review.The World Allergy Organization journal · 2025Review
- Levels of Exhaled Fraction of Nitric Oxide (FeNO) and Type 2 Biomarkers in Individuals Naturally Exposed to Helminth Parasites in a Tropical Region.International journal of molecular sciences · 2025Article
- Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- The Impact of the Quality of Care for Adults with Acute Asthma in the Emergency Department of a Tertiary Hospital: A 1-Year Follow-Up Study.Clinics and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Spanish Guideline on the Management of Asthma, better known by its acronym in Spanish GEMA, has been available for more than 20 years. Twenty-one scientific societies or related groups both from Spain and internationally have participated in the preparation and development of the updated edition of GEMA, which in fact has been currently positioned as the reference guide on asthma in the Spanish language worldwide. Its objective is to prevent and improve the clinical situation of people with asthma by increasing the knowledge of healthcare professionals involved in their care. Its purpose is to convert scientific evidence into simple and easy-to-follow practical recommendations. Therefore, it is not a monograph that brings together all the scientific knowledge about the disease, but rather a brief document with the essentials, designed to be applied quickly in routine clinical practice. The guidelines are necessarily multidisciplinary, developed to be useful and an indispensable tool for physicians of different specialties, as well as nurses and pharmacists. Probably the most outstanding aspects of the guide are the recommendations to: establish the diagnosis of asthma using a sequential algorithm based on objective diagnostic tests; the follow-up of patients, preferably based on the strategy of achieving and maintaining control of the disease; treatment according to the level of severity of asthma, using six steps from least to greatest need of pharmaceutical drugs, and the treatment algorithm for the indication of biologics in patients with severe uncontrolled asthma based on phenotypes. And now, in addition to that, there is a novelty for easy use and follow-up through a computer application based on the chatbot-type conversational artificial intelligence (ia-GEMA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.